Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Soliman H, Wagner S, Flake DD 2nd, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W.

Ann Surg Oncol. 2020 Mar;27(3):765-771. doi: 10.1245/s10434-019-08039-7. Epub 2020 Jan 6.

2.

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Curtis JR, Flake DD, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS.

Rheumatology (Oxford). 2019 May 1;58(5):874-883. doi: 10.1093/rheumatology/key367.

3.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.

Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.

4.

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.

Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.

Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.

5.

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.

Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.

Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.

6.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

7.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.

Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.

8.

Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.

Aramini B, Casali C, Stefani A, Bettelli S, Wagner S, Sangale Z, Hughes E, Lanchbury JS, Maiorana A, Morandi U.

Lung Cancer. 2016 Nov;101:82-87. doi: 10.1016/j.lungcan.2016.09.005. Epub 2016 Sep 6.

PMID:
27794412
9.

Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.

von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L.

Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6.

10.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.

Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.

11.

Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.

Rakha E, Pajares MJ, Ilie M, Pio R, Echeveste J, Hughes E, Soomro I, Long E, Idoate MA, Wagner S, Lanchbury JS, Baldwin DR, Hofman P, Montuenga LM.

Eur J Cancer. 2015 Sep;51(14):1897-903. doi: 10.1016/j.ejca.2015.07.015. Epub 2015 Jul 30.

PMID:
26235745
12.

Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.

Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer M, Scardino P.

Br J Cancer. 2015 Jul 28;113(3):382-9. doi: 10.1038/bjc.2015.223. Epub 2015 Jun 23.

13.

AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.

Virts EL, Jankowska A, Mackay C, Glaas MF, Wiek C, Kelich SL, Lottmann N, Kennedy FM, Marchal C, Lehnert E, Scharf RE, Dufour C, Lanciotti M, Farruggia P, Santoro A, Savasan S, Scheckenbach K, Schipper J, Wagenmann M, Lewis T, Leffak M, Farlow JL, Foroud TM, Honisch E, Niederacher D, Chakraborty SC, Vance GH, Pruss D, Timms KM, Lanchbury JS, Alpi AF, Hanenberg H.

Hum Mol Genet. 2015 Sep 15;24(18):5093-108. doi: 10.1093/hmg/ddv227. Epub 2015 Jun 17.

14.

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.

Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.

15.

Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.

Bueno R, Hughes E, Wagner S, Gutin AS, Lanchbury JS, Zheng Y, Archer MA, Gustafson C, Jones JT, Rushton K, Saam J, Kim E, Barberis M, Wistuba I, Wenstrup RJ, Wallace WA, Hartman AR, Harrison DJ.

J Thorac Oncol. 2015 Jan;10(1):67-73. doi: 10.1097/JTO.0000000000000365.

16.

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.

Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury JS, Stone S, Freedland SJ.

Int J Urol. 2014 Dec;21(12):1209-14. doi: 10.1111/iju.12571. Epub 2014 Aug 5.

17.

Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury JS, Sauter G, Brawer M, Stone S, Schlomm T.

J Urol. 2014 Aug;192(2):409-14. doi: 10.1016/j.juro.2014.02.003. Epub 2014 Feb 7.

PMID:
24508632
18.

Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES.

Clin Cancer Res. 2013 Nov 15;19(22):6261-71. doi: 10.1158/1078-0432.CCR-13-0596. Epub 2013 Sep 18.

19.

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):848-53. doi: 10.1016/j.ijrobp.2013.04.043. Epub 2013 Jun 5.

20.

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z; Transatlantic Prostate Group.

Br J Cancer. 2013 Jun 25;108(12):2582-9. doi: 10.1038/bjc.2013.248. Epub 2013 May 21.

21.

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR.

J Clin Oncol. 2013 Apr 10;31(11):1428-34. doi: 10.1200/JCO.2012.46.4396. Epub 2013 Mar 4.

PMID:
23460710
22.

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS.

Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.

23.

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.

Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.

PMID:
22406760
24.

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S; Transatlantic Prostate Group.

Br J Cancer. 2012 Mar 13;106(6):1095-9. doi: 10.1038/bjc.2012.39. Epub 2012 Feb 23.

25.

Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts.

Boonstra JJ, van Marion R, Douben HJ, Lanchbury JS, Timms KM, Abkevich V, Tilanus HW, de Klein A, Dinjens WN.

Genes Chromosomes Cancer. 2012 Mar;51(3):272-82. doi: 10.1002/gcc.20952. Epub 2011 Nov 12.

PMID:
22081516
26.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD 2nd, Wagner S, Gutin A, Lanchbury JS, Stone S; Transatlantic Prostate Group.

Lancet Oncol. 2011 Mar;12(3):245-55. doi: 10.1016/S1470-2045(10)70295-3.

27.

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.

Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2011 Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.

28.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.

29.

Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization.

Abkevich V, Iliev D, Timms KM, Tran T, Skolnick M, Lanchbury JS, Gutin A.

J Biomed Biotechnol. 2010;2010. pii: 386870. doi: 10.1155/2010/386870. Epub 2010 Jul 8.

30.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB.

J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6.

31.

Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.

Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG.

Am J Hum Genet. 2010 Jan;86(1):88-92. doi: 10.1016/j.ajhg.2009.12.008. Epub 2009 Dec 31.

32.

Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings.

Zhang L, Villa NY, Rahman MM, Smallwood S, Shattuck D, Neff C, Dufford M, Lanchbury JS, Labaer J, McFadden G.

J Proteome Res. 2009 Sep;8(9):4311-8. doi: 10.1021/pr900491n.

33.

Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses.

Mohamed MR, Rahman MM, Lanchbury JS, Shattuck D, Neff C, Dufford M, van Buuren N, Fagan K, Barry M, Smith S, Damon I, McFadden G.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9045-50. doi: 10.1073/pnas.0900452106. Epub 2009 May 18.

34.

IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease.

Roberts RL, Gearry RB, Hollis-Moffatt JE, Miller AL, Reid J, Abkevich V, Timms KM, Gutin A, Lanchbury JS, Merriman TR, Barclay ML, Kennedy MA.

Am J Gastroenterol. 2007 Dec;102(12):2754-61. Epub 2007 Sep 25.

PMID:
17894849
35.

Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation.

Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A, Lanchbury JS, Vyse TJ.

Hum Mol Genet. 2007 Mar 15;16(6):579-91. Epub 2006 Dec 22.

36.

Genomic DNA pooling for whole-genome association scans in complex disease: empirical demonstration of efficacy in rheumatoid arthritis.

Steer S, Abkevich V, Gutin A, Cordell HJ, Gendall KL, Merriman ME, Rodger RA, Rowley KA, Chapman P, Gow P, Harrison AA, Highton J, Jones PB, O'Donnell J, Stamp L, Fitzgerald L, Iliev D, Kouzmine A, Tran T, Skolnick MH, Timms KM, Lanchbury JS, Merriman TR.

Genes Immun. 2007 Jan;8(1):57-68. Epub 2006 Dec 7.

PMID:
17159887
37.

TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition.

Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, Trem D, Frank D, Jammulapati S, Neff CD, Iliev D, Gress R, He G, Frech GC, Adams TD, Skolnick MH, Lanchbury JS, Gutin A, Hunt SC, Shattuck D.

Hum Mol Genet. 2006 Sep 15;15(18):2709-20. Epub 2006 Aug 7.

PMID:
16893906
38.

Novel association suggests multiple independent QTLs within chromosome 5q21-33 region control variation in total humans IgE levels.

Ahmadi KR, Lanchbury JS, Reed P, Chiano M, Thompson D, Galley M, Line A, Lank E, Wong HJ, Strachan D, Spector TD.

Genes Immun. 2003 Jun;4(4):289-97.

PMID:
12761566
39.
40.

Development of rheumatoid arthritis is not associated with two polymorphisms in the Crohn's disease gene CARD15.

Steer S, Fisher SA, Fife M, Cuthbert A, Newton J, Wordsworth P, Lewis CM, Mathew CG, Lanchbury JS.

Rheumatology (Oxford). 2003 Feb;42(2):304-7.

PMID:
12595627
41.

Quantitative trait loci on chromosomes 1, 2, 3, 4, 8, 9, 11, 12, and 18 control variation in levels of T and B lymphocyte subpopulations.

Hall MA, Norman PJ, Thiel B, Tiwari H, Peiffer A, Vaughan RW, Prescott S, Leppert M, Schork NJ, Lanchbury JS.

Am J Hum Genet. 2002 May;70(5):1172-82. Epub 2002 Apr 9. Erratum in: Am J Hum Genet 2002 Sep;71(3):693.

42.

Genetic determinism in the relationship between human CD4+ and CD8+ T lymphocyte populations?

Ahmadi KR, Hall MA, Norman P, Vaughan RW, Snieder H, Spector TD, Lanchbury JS.

Genes Immun. 2001 Nov;2(7):381-7.

43.

Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome.

Bertolaccini ML, Atsumi T, Lanchbury JS, Caliz AR, Katsumata K, Vaughan RW, Kondeatis E, Khamashta MA, Koike T, Hughes GR.

Thromb Haemost. 2001 Feb;85(2):198-203.

PMID:
11246532
44.

Genetic polymorphism of IL-12 p40 gene in immune-mediated disease.

Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, Kaklamani E, Moutsopoulos H, Loughran TP Jr, Ollier WE, Panayi GS, Lanchbury JS.

Genes Immun. 2000 Feb;1(3):219-24.

45.

Genetic influence on peripheral blood T lymphocyte levels.

Hall MA, Ahmadi KR, Norman P, Snieder H, MacGregor AJ, Vaughan RW, Spector TD, Lanchbury JS.

Genes Immun. 2000 Oct;1(7):423-7.

46.

Interferon gamma gene in rheumatoid arthritis.

Lanchbury JS, Hall MA, Fife MS.

Lancet. 2000 Dec 23-30;356(9248):2192. No abstract available. Erratum in: Lancet 2001 Mar 31;357(9261):1048.

PMID:
11191570
47.

The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis.

Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, Soh C, Staines NA, Pappin DJ, Berlo SE, van Eden W, van Der Zee R, Lanchbury JS, Panayi GS.

J Immunol. 2001 Feb 1;166(3):1492-8.

48.

HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients.

Caliz R, Atsumi T, Kondeatis E, Amengual O, Khamashta MA, Vaughan RW, Lanchbury JS, Hughes GR.

Rheumatology (Oxford). 2001 Jan;40(1):31-6.

PMID:
11157139
49.

Single nucleotide polymorphisms and the future of genetic epidemiology.

Schork NJ, Fallin D, Lanchbury JS.

Clin Genet. 2000 Oct;58(4):250-64. Review.

PMID:
11076050
50.

Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region.

Fife MS, Fisher SA, John S, Worthington J, Shah CJ, Ollier WE, Panayi GS, Lewis CM, Lanchbury JS.

Arthritis Rheum. 2000 Aug;43(8):1673-8.

Supplemental Content

Loading ...
Support Center